Stay up to date on our latest NeuroBlu news and developments.

Event

ACNP 2022: ADHD Symptoms Differ Among Genders

NeuroBlu enables study conducted to explore how symptoms of ADHD differ among genders.

December 6, 2022

VIEW

New Release

Investigate Economic Burden with NeuroBlu Insights Explorer

Explore cost-effective treatments with the new Economic Burden dashboard in Insights Explorer.

November 23, 2022

VIEW

Event

DGPPN 2022: Holmusk Shares Insights on Schizophrenia, COVID - 19

Holmusk shares insights from a study conducted to understand how the COVID-19 pandemic impacted illness severity and healthcare utilization.

November 23, 2022

VIEW

Event

ISPOR Europe 2022: Holmusk Presents Real-world Evidence on Hospitalization Risk

Holmusk's study sheds new light on the association between symptoms and hospitalization risk in people with behavioral health disorders.

November 7, 2022

VIEW

New Release

Get faster insights with more granular data and notifications on shared work

New data with rich measurements, notifications on shared work, and updates to Insights Explorer.

November 2, 2022

VIEW

Event

NAHDO 2022: Holmusk Shares First Natural Language Processing Model Trained for Behavioral Health

NeuroBlu database powers Holmusk's natural language processing model specifically trained for behavioral health clinical data.

October 25, 2022

VIEW

Event

AACAP 2022: Holmusk Presents Real-world Evidence on ADHD

NeuroBlu enables study providing evidence on relationship between executive functioning and illness severity in patients with ADHD.

October 21, 2022

VIEW

Event

ECNP Congress 2022: Holmusk Shares Real-world Evidence on Schizophrenia

Holmusk shares real-world evidence generated using longitudinal behavioral health data on schizophrenia.

October 20, 2022

VIEW

General

Video Series : Power up your research with 1M+ patient lives data and project sharing

In this on-demand video we cover NeuroBlu’s recent milestone release which brings data and analytics tools to fuel your research.

October 17, 2022

VIEW

Event

AMCP Nexus 2022: Holmusk Presents Evidence on Antipsychotic Prescribing for Patients with Schizophrenia

Holmusk offers real-world evidence to shed new light on antipsychotic prescribing patterns.

October 14, 2022

VIEW

General

Video Series : Insights Explorer for no-code exploration of real-world behavioral health data

In this on-demand video see how Insights Explorer can help uncover powerful information in just a few clicks.

October 3, 2022

VIEW

Event

Psych Congress 2022: Holmusk Presents Two Posters on Behavioral Health Real-world Evidence

Leveraging real-world data to generate new insights and answer pressing behavioral health questions.

September 18, 2022

VIEW

New Release

Gain better insights with 1M+ patient lives data and break silos by sharing projects

NeuroDB 22R3 data release with new partners and measures along with project sharing in NeuroBlu.

September 15, 2022

VIEW

New Release

Accelerate drug impact comparison and easily switch datasets

Compare the impact of drugs in Insights Explorer and easily switch datasets.

September 1, 2022

VIEW

General

Video Series : Expanding the behavioral health evidence blueprint with NeuroDB 22R2 and CDM 2.0

Updated data architecture to enhance data quality and improve user experience.

August 11, 2022

VIEW

New Release

Insights Explorer, new no-code feature for faster analysis in NeuroBlu Research

New Insights Explorer feature for no-code exploration of real-world behavioral health data.

August 8, 2022

VIEW

New Release

Enhanced Cohort Builder for tailored analysis

Improved Cohort Builder with index date and refined filtering on CGI-S measurements.

August 1, 2022

VIEW

New Release

Enhanced Common Data Model and other features

Improved data architecture for powerful analyses. Accelerate research by importing/exporting codes.

July 1, 2022

VIEW

Event

Holmusk Speaks About NeuroBlu at Going Digital: Behavioral Health Tech Conference

Recent progress and future plans on transforming behavioral health through real-world evidence.

June 10, 2022

VIEW

Event

Holmusk Presents on NeuroBlu Research Capabilities at European Congress of Psychiatry

NeuroBlu enables analysis of real-world data, in a secure and accessible environment, to answer challenging questions about behavioral health.

June 4, 2022

VIEW

Event

Holmusk Presents Science at American Society of Clinical Psychopharmacology

Holmusk shared findings from study investigating relationship between symptom burden and outcomes in patients with a diagnosis of schizophrenia.

June 1, 2022

VIEW

Event

APA 2022: Holmusk Presents Two Posters Showing New Insights from Real-World Data at American Psychiatric Association

Real-world data reveals differences between diagnoses and phenotypes, and how polypharmacy affects functioning in patients.

May 24, 2022

VIEW

Event

ISPOR 2022: Holmusk Presents Real-world Evidence on Comorbid Substance Use Disorder and Schizophrenia Severity

Holmusk offers new insights on the association between comorbid substance use disorders and illness severity in people with schizophrenia.

May 18, 2022

VIEW

Publication

ISPOR 2022: Holmusk Presents Study on Antidepressant Medications’ Impact on Difficult-to-Treat Depression

Holmusk offers new real-world evidence into patients with difficult-to-treat depression.

May 16, 2022

VIEW

Publication

Holmusk Announces Publication of Seminal Paper on Real-World Evidence (RWE) Platform NeuroBlu

Holmusk publishes paper in BMJ Open, centering on dataset available in NeuroBlu, and platform capabilities.

April 26, 2022

VIEW

Publication

Abstracts Present New Real-world Evidence at Annual Schizophrenia Conference

Holmusk provides new insights into schizophrenia that could support more individualized care pathways.

April 8, 2022

VIEW

New Release

Expanded real-world data, on-demand help, and other updates

Expanded dataset to enhance real-world impact. Boost efficiency with Help & Resources.

April 1, 2022

VIEW

New Release

Improved search experience and download visualizations

Filter search results and view data by categories. Download cohort visualizations to document your research.

February 4, 2022

VIEW

Publication

Study Results in New Information about ADHD Medications for Young Children

Holmusk presents results from the largest analysis to date evaluating treatment of ADHD for young children.

January 15, 2022

VIEW

Publication

Holmusk and JPS Announce New Publication on Factors Affecting Buprenorphine Treatment Attrition in Opioid Use Disorder

Study uses Real-World Data to describe important patterns in the treatment of opioid use disorder.

January 5, 2022

VIEW

New Release

Introducing NeuralRiskModels package and other updates

Build dynamic risk models. New functions in Code Studio to conduct research studies faster.

November 1, 2021

VIEW

Publication

Relationship Between Polypharmacy and Clinical Functioning in Patients With ADHD: A Retrospective Analysis of Real-World Data

Holmusk publishes abstract in American Academy of Child and Adolescent Psychiatry (AACAP) 68th Annual Meeting.

October 18, 2021

VIEW

New Release

Introducing guided research study tutorials, product and feature tours, and other updates

Enhanced experience with smoother onboarding journey, new CGI-S filter and new project organization tools.

October 12, 2021

VIEW

Publication

Insights from NeuroBlu’s Real-World Dataset: Buprenorphine Treatment Retention in Individuals with Opioid Use Disorder

Holmusk presents at American Society for Clinical Pathology (ASCP) 2021 Annual Meeting.

August 22, 2021

VIEW

Event

NeuroBlu Award: Call for Proposals

Holmusk invites start-ups and academics to submit proposals for projects using NeuroBlu.

August 21, 2021

VIEW

New Release

Introducing Python

Use Python to perform customized research studies on NeuroBlu.

July 1, 2021

VIEW

New Release

Introducing BluSuite, Project Notes and other updates

Conduct advanced analytics with ease, with enhanced visualizations and documentation of research notes.

March 31, 2021

VIEW
Back to top
Contact us